Design of clinical trial: End points considerations in the selection of end points for aids clinical trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 3, Issue , 1990, Pages S64-S68

  Amato, David A ^a   Lagakos, Stephen W ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trials; End points

Indexed keywords

CD4 ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; MEDICAL RESEARCH; NONHUMAN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; ANTIGENS, CD4; CLINICAL TRIALS; GENE PRODUCTS, GAG; HIV CORE PROTEIN P24; HUMAN; SUPPORT, U.S. GOV'T, P.H.S.; VIRAL CORE PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84938476149     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley &Sons, Inc., 1983.
2. Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer clinical trials: methods and practice. Oxford: Oxford University Press, 1984.
3. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials, 2nd edition. Littleton, MA: PSG Publishing Company, 1985.
4. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34:585-612.
5. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley &Sons, Inc., 1980.
6. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-91.
7. Volberding PA, Lagakos S, Koch M, et al. The efficacy of AZT in patients with asymptomatic HIV infection having less than 500 CD4 cells. N Engl J Med 1990; 322:941-9.
8. Moss AR. Predicting who will progress to AIDS. Br J Med 1988; 297:1067-8.